Target expression details
| Target General Information | |||||
|---|---|---|---|---|---|
| Target ID | T10191 | ||||
| Target Name | T-cell surface glycoprotein CD4 | ||||
| Synonyms | T-cell surface antigen T4/Leu-3; CD4 | ||||
| Target Type | Clinical Trial | ||||
| Gene Name | CD4 | ||||
| Biochemical Class | Immunoglobulin | ||||
| UniProt ID | CD4_HUMAN | ||||
| Target Gene Expression Profiles in the Disease-Relevant Drug Targeted Tissue of the Patients and Healthy Individuals | |||||
| Disease | Psoriasis | ||||
| Example drug | BT-061 | Phase 2 | [1], [2], [3] | ||
| Tissue | Skin | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: -0.23 Z-score: -0.79 P-value: 2.23E-07 |
||||
| Level of differential expression between the patients in the disease section of the tissue and the patients in the normal section of the tissue adjacent to the disease section | Fold-change: 0.26 Z-score: 1.06 P-value: 2.45E-15 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Rheumatoid arthritis | ||||
| Example drug | IDEC-151 | Discontinued in Phase 2 | [4], [3] | ||
| Tissue | Synovial tissue | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: 0.67 Z-score: 2.62 P-value: 9.36E-04 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Target Gene Expression Profiles in Other Tissues of Healthy Individuals | |||||
|
|||||
| Reference | |||||
| REF 1 | ClinicalTrials.gov (NCT01072383) Safety and Efficacy of Multiple Doses of BT061 in Patients With Moderate to Severe Chronic Plaque Psoriasis. U.S. National Institutes of Health. | ||||
| REF 2 | A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway. Immunol Cell Biol. 2015 Apr;93(4):396-405. | ||||
| REF 3 | NCBI GEO: archive for functional genomics data sets--update. | ||||
| REF 4 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007359) | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.